Navigation Links
Reportlinker Adds Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Date:4/14/2011

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0479826/Bone-Metastases-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Bone Metastases Therapeutics market. The report identifies the key trends shaping and driving the global Bone Metastases Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bone Metastases Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Bone Metastases Therapeutics market. Its Scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Bone Metastases Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Bone Metastases Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Bone Metastases Therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in Bone Metastases Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Bone Metastases Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Bone Metastases Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Bone Metastases Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Bone Metastasis Therapeutics: Introduction 6

2.1 Disease Overview 6

2.2 Epidemiology 7

2.3 Etiology and Pathophysiology 8

2.4 Signs and Symptoms 10

2.5 Diagnosis 11

2.6 Treatment and Management Pattern: 13

2.6.1 Systemic Therapy: 13

2.6.2 External Beam Radiation Therapy 14

2.7 GlobalData Pipeline Report Guidance 15

3 Bone Metastases Therapeutics: Market Characterization 16

3.1 Bone Metastases Therapeutics Market Size (2005-2010) – Global 16

3.2 Bone Metastases Therapeutics Market Forecast (2010-2017) – Global 17

3.3 Bone Metastases Therapeutics Market Size (2005-2010) – The US 18

3.4 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The US 19

3.5 Bone Metastases Therapeutics Market Size (2005-2010) – France 20

3.6 Bone Metastases Therapeutics Market Forecasts (2010-2017) – France 21

3.7 Bone Metastases Therapeutics Market Size (2005-2010) – Germany 22

3.8 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Germany 23

3.9 Bone Metastases Therapeutics Market Size (2005-2010) – Italy 24

3.10 Bone Metastases Therapeutics Market Forecast (2010-2017) – Italy 25

3.11 Bone Metastases Therapeutics Market Size (2005-2010) – Spain 26

3.12 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Spain 27

3.13 Bone Metastases Therapeutics Market Size (2005-2010) – The UK 28

3.14 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The UK 29

3.15 Bone Metastases Therapeutics Market Size (2005-2010) – Japan 30

3.16 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Japan 31

3.17 Drivers and Barriers for the Bone Metastases Therapeutics Market 32

3.17.1 Drivers for the Bone Metastases Therapeutics Market 32

3.17.2 Barriers for the Bone Metastases Therapeutics Market 32

3.18 Opportunity and Unmet Need Analysis 32

3.19 Key Takeaway 33

4 Bone Metastases Therapeutics: Competitive Assessment 34

4.1 Overview 34

4.2 Strategic Competitor Assessment 34

4.3 Product Profiles for the Major Marketed Products in the Bone Metastases Therapeutics Market 35

4.3.1 Zometa (Zoledronate) 35

4.3.2 Xgeva (denosumab) 36

4.3.3 Bondronat (ibandronic acid) 37

4.4 Key Takeaway 37

5 Bone Metastases Therapeutics: Pipeline Assessment 38

5.1 Overview 38

5.2 Strategic Pipeline Assessment 38

5.3 Bone Metastases Therapeutics Pipeline – Pipeline by Phases of Development 38

5.3.1 Bone Metastases Therapeutics – Phase III Pipeline 38

5.3.2 Bone Metastases Therapeutics – Phase II Pipeline 39

5.3.3 Bone Metastases Therapeutics – Phase I Pipeline 39

5.3.4 Bone Metastases Therapeutics – Preclinical Pipeline 39

5.3.5 Technology Trends Analytic Framework 40

5.4 Bone Metastases Therapeutics Market – Clinical Pipeline by Mechanism of Action 41

5.5 Bone Metastases Therapeutics – Promising Drugs Under Clinical Development 42

5.6 Molecule Profile for Promising Drugs Under Clinical Development 43

5.6.1 Alpharadin (radium-223 chloride) 43

5.6.2 Orazol (Zoledronic acid) 43

5.7 Key Takeaway 44

6 Bone Metastases Therapeutics: Clinical Trials Mapping 45

6.1 Clinical Trials by Country (US, EU and Japan) 45

6.2 Clinical Trials by Phase 46

6.3 Clinical Trials by Trial Status 47

6.4 Prominent Sponsors 48

6.5 Top Companies Participating in Bone Metastases Therapeutics Clinical Trials 50

7 Bone Metastases Therapeutics: Strategic Assessment 51

7.1 Key Events Impacting the Future Market 51

7.2 Bone Metastases Therapeutics: Implications for Future Market Competition 52

8 Bone Metastases Therapeutics: Future Players 53

8.1 Introduction 53

8.2 Company Profiles 54

8.2.1 Novartis AG 54

8.2.2 Amgen Inc. 60

8.2.3 Bayer AG 63

8.2.4 Algeta ASA 67

8.2.5 Merrion Pharmaceuticals Plc 69

8.2.6 Other Companies in the Bone Metastases Therapeutics Market 70

9 Bone Metastases Therapeutics: Licensing and Partnership Deals 72

10 Bone Metastases Therapeutics: Appendix 76

10.1 Market Definitions 76

10.2 Abbreviations 76

10.3 Research Methodology 77

10.3.1 Coverage 77

10.3.2 Secondary Research 77

10.3.3 Forecasting 78

10.3.4 Primary Research 80

10.3.5 Expert Panel Validation 80

10.4 Contact Us 80

10.5 Disclaimer 80

10.6 Bibliography 81

1.1 List of Tables

Table 1: Metastatic Bone Disease is Prevalent in Many Types of Cancer 6

Table 2: Prevalence of Bone Metastases in Different Cancer Types, 2010 7

Table 3: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010 16

Table 4: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017 17

Table 5: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010 20

Table 6: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017 21

Table 7: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010 22

Table 8: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017 23

Table 9: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010 24

Table 10: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017 25

Table 11: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010 26

Table 12: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017 27

Table 13: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010 28

Table 14: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29

Table 15: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010 30

Table 16: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017 31

Table 17: Bone Metastases Therapeutics – Phase III Pipeline, 2010 38

Table 18: Bone Metastases Therapeutics – Phase II Pipeline, 2010 39

Table 19: Bone Metastases Therapeutics – Phase I Pipeline, 2010 39

Table 20: Bone Metastases Therapeutics – Preclinical Pipeline, 2010 39

Table 21: Bone Metastases Therapeutics – Most Promising Drugs Under Clinical Development, 2010 42

Table 22: Bone Metastases Therapeutics – Clinical Trials by Country, 2011 45

Table 23: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011 46

Table 24: Bone Metastases Therapeutics - Clinical Trials by Status, 2011 47

Table 25: Bone Metastases Therapeutics - Prominent Sponsors, 2011 49

Table 26: Bone Metastases Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50

Table 27: Novartis – Oncology Pipeline, 2010 56

Table 28: Novartis Deals, 2009-2010 57

Table 29: Amgen Inc. – Bone Metastases, Pipeline, 2010 61

Table 30: Amgen Inc. Deals, 2009-2010 62

Table 31: Bayer AG – Oncology Pipeline, 2010 64

Table 32: Bayer AG Deals, 2009-2010 65

Table 33: Algeta ASA Pharmaceuticals – Oncology, Pipeline, 2010 68

Table 34: Algeta ASA Pharmaceuticals – Bone Metastases, Pipeline, 2010 68

Table 35: Algeta ASA Deals, 2009-2010 68

Table 36: Merrion Pharmaceuticals – Oncology Pipeline, 2010 69

Table 37: Merrion Pharmaceuticals – Oncology Pipeline, 2010 69

Table 38: Merrion AG Deals, 2009-2010 70

Table 39: Bone Metastases Pain Therapeutics Market – Future Players 70

Table 40: Bone Metastases Therapeutics, Global, Deals 72

1.2 List of Figures

Figure 1: (a) Osteolytic lesions; (b) Osteoblastic lesion 7

Figure 2: Mechanism of Tumor Metastasis to Bone 8

Figure 3: Prevalence of Skeletal-Related Events in Patients with Metastatic Bone Disease not Treated with Bisphosphonates 9

Figure 4: Diagnosis of Bone Metastases 11

Figure 5: Algorithm for Imaging for Cancer Patients in the US 12

Figure 6: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010 16

Figure 7: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017 17

Figure 8: Bone Metastases Therapeutics Market, The US, Revenue ($m), 2005–2010 18

Figure 9: Bone Metastases Therapeutics Market, The US, Forecasts ($m), 2010–2017 19

Figure 10: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010 20

Figure 11: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017 21

Figure 12: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010 22

Figure 13: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017 23

Figure 14: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010 24

Figure 15: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017 25

Figure 16: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010 26

Figure 17: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017 27

Figure 18: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010 28

Figure 19: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29

Figure 20: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010 30

Figure 21: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017 31

Figure 22: Opportunity and Unmet Need in the Bone Metastases Therapeutics Market 33

Figure 23: Bone Metastases Therapeutics – Strategic Competitor Assessment, 2010 34

Figure 24: Bone Metastases Therapeutics – Pipeline by Phase of Development, 2010 38

Figure 25: Bone Metastases Therapeutics – Technology Trends Analytics Framework, 2010 40

Figure 26: Bone Metastases Therapeutics – Technology Trends Analytics Framework – Description, 2010 40

Figure 27: Bone Metastases Therapeutics – Pipeline by Mechanism of Action, 2010 41

Figure 28: Bone Metastases Therapeutics – Clinical Trials by Country, 2011 45

Figure 29: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011 46

Figure 30: Bone Metastases Therapeutics - Clinical Trials by Status, 2011 47

Figure 31: Bone Metastases Therapeutics - Overall Sponsors, 2011 48

Figure 32: Bone Metastases Therapeutics - Prominent Sponsors, 2011 48

Figure 33: Bone Metastases Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50

Figure 34: Bone Metastases Therapeutics Market, Drivers and Restraints, 2011 51

Figure 35: Implications for Future Market Competition in Bone Metastases, 2011 52

Figure 36: Bone Metastases Therapeutics – Pipeline by Company, 2011 53

Figure 37: GlobalData Market Forecasting Model 79Novartis AG

Amgen Inc.

Bayer AG

Algeta ASA

Merrion Pharmaceuticals Plc

To order this report:

: Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
2. Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
3. Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report
4. Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report
5. Reportlinker Adds Immuno Chemistry Reagents, Analyzers and Test Kits - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
6. Reportlinker Adds Europe Neurology Devices Market Outlook to 2017
7. Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017
8. Reportlinker Adds Asia-Pacific Nephrology and Urology Devices Market Outlook to 2017
9. Reportlinker Adds Cardiac Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecast to 2017
10. Reportlinker Adds Infectious Immunology Reagents, Instruments and Test Kits - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):